| 4.14 -0.22 (-5.05%) | 08-31 00:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
On August 30, 2022, Second Sight Medical Products, Inc. underwent a reverse merger, resulting in its acquisition by Nano Precision Medical, Inc. Previously, Second Sight specialized in the creation, production, and commercialization of implantable visual prosthetics, with the goal of restoring artificial vision to individuals who are blind. The company's overarching objective was to advance technologies designed to aid the sight-impaired community. A notable offering was the Orion Visual Cortical Prosthesis System, an implanted cortical stimulator developed to deliver functional artificial vision. This system targeted individuals suffering from blindness caused by a range of conditions, such as glaucoma, diabetic retinopathy, damage or disease affecting the optic nerve, and other forms of eye injury. Established in 1998, the company was based in Sylmar, California.
Mon, 20 Oct 2025
Blind patients read again with smart glasses-linked eye implant - The Verge
Tue, 15 Aug 2023
Second Sight’s Implant Technology Gets a Second Chance - IEEE Spectrum
Thu, 17 Feb 2022
Bionic eye recipients left in the dark with obsolete tech - Axios
Thu, 17 Feb 2022
Bionic eyes: Obsolete tech leaves patients in the dark - BBC
Thu, 17 Feb 2022
'Fantastic technology and a lousy company': Second Sight's 'bionic eyes' have gone obsolete while still implanted, report finds - Fierce Biotech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|